Roche Giredestrant NDA Accepted by FDA in Breast Cancer
Basel, Switzerland — February 20, 2026: Roche announced that the U.S. Food and Drug Administration (FDA) has accepted its...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
Basel, Switzerland — February 20, 2026: Roche announced that the U.S. Food and Drug Administration (FDA) has accepted its...
RESEARCH TRIANGLE PARK, N.C., February 20, 2026 — IQVIA announced continued expansion of its healthcare intelligence and advanced analytics...
